Richard Mills, MD
Internal Medicine · Marietta, GANPI 1407848716
Payments from drug & device makers
Across 235 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$587
- AbbVie$413
- Pfizer$356
- Takeda Pharmaceuticals U.S.A., Inc.$239
- AstraZeneca$230
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$197
- plus $2K from 29 others
What the payments were for
- Consulting fees$411%
- Food & beverage$3,77799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 57 | $587 |
| AbbVie(2 entities) | 27 | $413 |
| Pfizer | 16 | $356 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $239 |
| AstraZeneca | 13 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $197 |
| Grifols USA, LLC | 11 | $196 |
| Octapharma USA, Inc. | 3 | $130 |
| Antares Pharma, Inc. | 8 | $114 |
| Esperion Therapeutics, Inc. | 6 | $107 |
| Merck | 6 | $103 |
| Lilly USA, LLC | 6 | $98 |
| Novo Nordisk | 7 | $95 |
| Lundbeck LLC | 3 | $83 |
| Novartis | 4 | $80 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| Sumitomo Pharma America, Inc. | 7 | $76 |
| GSK | 4 | $72 |
| Astellas Pharma US Inc | 4 | $72 |
| Eisai Inc. | 4 | $65 |
| Azurity Pharmaceuticals, Inc. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| ADMA Biomanufacturing LLC | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Optinose US, Inc. | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Abbott | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,818 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $91,863 |
| EliquisApixaban | 50 | $39,529 |
| OzempicSemaglutide | 36 | $33,176 |
| FarxigaDapagliflozin Propanediol | 35 | $32,363 |
| XareltoRivaroxaban | 21 | $21,421 |
| Xtampza ErOxycodone Myristate | 25 | $20,709 |
| MounjaroTirzepatide | 19 | $19,646 |
| JardianceEmpagliflozin | 25 | $18,746 |
| InvokanaCanagliflozin | 24 | $15,219 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 51 | $14,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,631 |
| MyrbetriqMirabegron | 18 | $10,707 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 38 | $8,154 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,855 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $7,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCXembify | $196 | $91,86313 claims |
| PfizerEliquis, Abrysvo | $356 | $44,29165 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta | $72 | $43,122128 claims |
| Johnson & JohnsonXarelto, Invokana | $20 | $36,64045 claims |
| Novo NordiskOzempic | $95 | $33,17636 claims |
| AstraZenecaFarxiga | $230 | $32,36335 claims |
| Lilly USA, LLCMounjaro | $98 | $19,64619 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $10,70718 claims |
| AbbVieSynthroid | $413 | $4,42849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Marietta
- Ebon BourneMarietta$242K
- Ramprasad SubramaniamMarietta$142K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.